Representative Bob Onder has formally raised concerns regarding the United States' heavy reliance on foreign pharmaceutical supplies, framing the issue as a significant national security vulnerability. According to Onder, the current dependence on international manufacturing chains leaves the American public susceptible to risks, specifically citing recent instances of drug contamination as evidence that the supply chain is compromised.

To address these concerns, Onder is calling for a strategic shift toward rebuilding domestic pharmaceutical manufacturing capacity. The proposal suggests that by producing essential medications within the United States, the government can better ensure the safety and reliability of the nation's medicine supply. The argument centers on the idea that medical independence is a critical component of national security, rather than just a matter of economic or healthcare policy. While the proposal highlights the potential for increased safety, it also underscores the logistical and economic challenges inherent in shifting manufacturing back to the U.S. from established global markets. As of now, the discussion remains focused on the potential risks of the status quo and the necessity of legislative action to incentivize domestic production.